Requirement for safety monitoring for approved multiple sclerosis therapies: an overview

Monoclonal Antibodies and Progressive Multifocal Leukoencephalopathy

(2014) Daniel L. Keene et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

JC virus antibody status underestimates infection rates

(2013) Joseph R. Berger et al.   ANNALS OF NEUROLOGY

Multiple sclerosis treatment and infectious issues: update 2013

(2013) A. Winkelmann et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Central Nervous System Herpes Simplex and Varicella Zoster Virus Infections in Natalizumab-Treated Patients

(2013) A. J. Fine et al.   CLINICAL INFECTIOUS DISEASES

Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy

(2013) Aran Groves et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy

(2013) Bob W. van Oosten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Manufacturer's Response to Case Reports of PML

(2013) Marianne T. Sweetser et al.   NEW ENGLAND JOURNAL OF MEDICINE

PML in a Patient Treated with Fumaric Acid

(2013) Ummehan Ermis et al.   NEW ENGLAND JOURNAL OF MEDICINE

New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis

(2012) Edward J. Fox et al.   CURRENT OPINION IN NEUROLOGY

Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab

(2012) B.K. Kleinschmidt-DeMasters et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

(2012) Christian Confavreux et al.   Multiple Sclerosis Journal

Vaccination against infection in patients with multiple sclerosis

(2012) Micha Loebermann et al.   Nature Reviews Neurology

Teriflunomide added to interferon-  in relapsing multiple sclerosis: A randomized phase II trial

(2012) M. S. Freedman et al.   NEUROLOGY

Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review

(2012) E. Lu et al.   NEUROLOGY

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mitoxantrone Induces Natural Killer Cell Maturation in Patients with Secondary Progressive Multiple Sclerosis

(2012) Coralie Chanvillard et al.   PLoS One

Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis

(2011) R. A. Linker et al.   BRAIN

Immune mechanisms of new therapeutic strategies in MS — Teriflunomide

(2011) Malte C. Claussen et al.   CLINICAL IMMUNOLOGY

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

(2011) Ludwig Kappos et al.   LANCET NEUROLOGY

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

(2011) M. Cossburn et al.   NEUROLOGY

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

(2011) Paul O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-JC virus antibodies: Implications for PML Risk Stratification

(2010) Leonid Gorelik et al.   ANNALS OF NEUROLOGY

Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material

(2010) J. S. CROWE et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Alemtuzumab and multiple sclerosis: therapeutic application

(2010) Minagar Alireza et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

(2010) Chris H Polman et al.   LANCET NEUROLOGY

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

(2010) C. Ford et al.   Multiple Sclerosis Journal

Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS

(2010) E. Kingwell et al.   NEUROLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

(2010) J. W. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The relation between inflammation and neurodegeneration in multiple sclerosis brains

(2009) Josa M. Frischer et al.   BRAIN

Melanoma complicating treatment with Natalizumab (Tysabri) for multiple sclerosis

(2009) Azza Ismail et al.   JOURNAL OF NEUROLOGY

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

INTERFERON BETA TREATMENT DOES NOT INDUCE ORGAN-SPECIFIC AUTOANTIBODIES IN MULTIPLE SCLEROSIS

(2009) T. Menge et al.   NEUROLOGY

Interferon-  mechanisms of action in multiple sclerosis

(2009) S. Dhib-Jalbut et al.   NEUROLOGY

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Melanoma Complicating Treatment with Natalizumab for Multiple Sclerosis

(2008) John T. Mullen et al.   NEW ENGLAND JOURNAL OF MEDICINE